This is a snippet of the transcript, sign up to read more.
Regarding the Cytiva piece, I was surprised it was approved. Cytiva still has about 80% of the market in chromatography resins, which is huge. They could never get a filtration company and were in competition with Danaher for buying Pall. The same goes for Thermo Fisher. The pairing of Pall and Cytiva has been great for them as we move forward, as long as they don't become too insensitive to customer demands. Sometimes with big companies, that can happen.
This is a snippet of the transcript, sign up to read more.
Thermo Fisher, Pall Cytiva, Sartorius, and Millipore captured market share by giving away razors, at cost ,to capture consumables. Now that facility expansions have slowed down, I think there will be a more challenging road ahead for them in the next couple of years.
This is a snippet of the transcript, sign up to read more.
The available capacity today compared to a year ago is quite drastic. I don't have exact numbers, but I suspect that where people were close to capacity, now only about 70% is utilized. I think demand for future builds will drop a bit until we know more about the recession or non-recession. From what I've heard, funding is not as readily available, and people with ideas have to justify their business plans, with VCs being more disciplined in their decision-making.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research